Pseudomyxoma Peritonei Derived From Appendiceal Mucinous Neoplasm
Article Sidebar
Main Article Content
Abstract
Pseudomyxoma peritonei (PMP) is an uncommon clinical entity characterized by progressive accumulation of mucinous material within the peritoneal cavity, most frequently originating from ruptured appendiceal mucinous neoplasms. The disease typically follows an indolent course, with nonspecific early symptoms leading to delayed diagnosis and advanced disease at presentation. This review summarizes current evidence regarding the pathogenesis, clinical manifestations, histopathological classification, and molecular features of PMP. The standard treatment remains cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC), which has demonstrated favorable long-term outcomes in appropriately selected patients. Alternative therapeutic approaches are also discussed in the context of recurrent disease or patients deemed unsuitable for extensive surgery. Further research is warranted to clarify the role of these emerging modalities and to optimize individualized treatment strategies for this rare condition.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
บทความทีตีพิมพ์ในวารสารโรคมะเร็งนี้ถือว่าเป็นลิขสิทธิ์ของมูลนิธิสถาบันมะเร็งแห่งชาติ และผลงานวิชาการหรือวิจัยของคณะผู้เขียน ไม่ใช่ความคิดเห็นของบรรณาธิการหรือผู้จัดทํา
References
Li X, Liu G, Wu W. Progress in biological research and treatment of pseudomyxoma peritonei. Cancers.2024;16(7):1406. doi.org/10.3390/cancers16071406
Pastier C, De Hingh IHJT, Goéré D. New insights in the management of pseudomyxoma peritonei. J Surg Oncol. 2024;130(6):1316–25. doi:10.1002/jso.27842
Nougaret S, Guiu B, Ronot M, et al. Pseudomyxoma peritonei: a comprehensive imaging review. Radiographics. 2012;32(7):2021–39
WHO Classification of Tumours Editorial Board. Digestive system tumours. 5th ed. Lyon (France): International Agency for Research on Cancer; 2019. (WHO classification of tumours series)
Govaerts K, Lurvink RJ, De Hingh IHJT, et al. Appendiceal tumours and pseudomyxoma peritonei: literature review with PSOGI/EURACAN clinical practice guidelines for diagnosis and treatment. Eur J Surg Oncol. 2021;47(1):11–35
Carr NJ, Cecil TD, Mohamed F, et al. A consensus for classification and pathologic reporting of pseudomyxoma peritonei and associated appendiceal neoplasia: the results of the Peritoneal Surface Oncology Group International (PSOGI) modified Delphi process. Am J Surg Pathol. 2016;40(1):14–26
Morano WF, Gleeson E, Sullivan KM, et al. A review of the histopathologic subtypes of appendiceal neoplasms. Surg Oncol. 2018;27(2):161–9
Foote MB, Walch H, Chatila W, et al. Molecular classification of appendiceal adenocarcinoma. J Clin Oncol. 2023;41(8):1553–64. doi:10.1200/JCO.22.01392
Moaven O, Su J, Jin G, et al. Clinical implications of genetic signatures in appendiceal cancer patients with incomplete cytoreduction/HIPEC. Ann Surg Oncol. 2020;27(13):5016–23. doi:10.1245/s10434-020-08841-8
Ladel L, Tan WY, Jeyakanthan T, et al. The promise of epigenetics research in the treatment of appendiceal neoplasms. Cells. 2023;12(15):1962. doi:10.3390/cells12151962
Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30(20):2449–56
Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol. 2006;7(1):69–76
Levine EA, Votanopoulos KI, Shen P, et al. The role of HIPEC in the management of pseudomyxoma peritonei. Ann Surg Oncol. 2021;28(10):5447–56
Kusamura S, Baratti D, Deraco M. Multidimensional analysis of prognostic factors in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2012;19(13):4028–35
Glehen O, Gilly FN, Boutitie F, et al. A multicenter study of cytoreductive surgery and intraperitoneal chemohyperthermia for pseudomyxoma peritonei of appendiceal origin. Ann Surg. 2010;252(2):320–5
Godfrey EL, Mahoney F, Bansal VV, et al. Consensus guideline for the management of patients with appendiceal tumors, part 1: appendiceal tumors without peritoneal involvement. Ann Surg Oncol. Published online 2025. doi:10.1245/s10434-025-17359-w
Godfrey EL, Mahoney F, Bansal VV, et al. Consensus guideline for the management of patients with appendiceal tumors, part 2: appendiceal tumors with peritoneal involvement. Ann Surg Oncol. Published online 2025. doi:10.1245/s10434-025-17364-z
Kusamura S, Bhatt A, van Der Speeten K, et al. Review of 2022 PSOGI/RENAPE consensus on HIPEC. J Surg Oncol. 2024;130:1290–8. doi:10.1002/jso.278853
Kusamura S, Delhorme JB, Taibi A, et al. The 2022 PSOGI international consensus on HIPEC regimens for peritoneal malignancies: pseudomyxoma peritonei. Ann Surg Oncol. 2024;31:6262–73. doi:10.1245/s10434-024-15646-6
Kusamura S, Barretta F, Yonemura Y, et al. The role of hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei after cytoreductive surgery. JAMA Surg. 2021;156(3):e206363. doi:10.1001/jamasurg.2020.6363
Delhorme JB, Elias D, Varatharajah S, et al. Can a benefit be expected from surgical debulking of unresectable pseudomyxoma peritonei? Ann Surg Oncol. 2016;23(5):1618–24. doi:10.1245/s10434-015-5019-9
Wang B, Ma R, Shi G, et al. Hyperthermic intraperitoneal chemotherapy in patients with incomplete cytoreduction for appendiceal pseudomyxoma peritonei: a 10-year treatment experience in China. Orphanet J Rare Dis. 2024;19(1):8. doi:10.1186/s13023-023-02995-w
Solass W, Sempoux C, Detry O, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable peritoneal carcinomatosis of appendiceal origin. Pleura Peritoneum. 2018;3(2):20180112
Sgarbura O, Hübner M, Alyami M, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in patients with peritoneal carcinomatosis: a systematic review. Cancers (Basel). 2021;13(15):3696
Mortensen MB, Casella F, Düzgün Ö, et al. Second annual report from the ISSPP PIPAC database. Pleura Peritoneum. 2023;8(4):141–6. doi:10.1515/pp-2023-0047
Wen HK, Valle SJ, Morris DL. Bromelain and acetylcysteine (BromAc®): a novel approach to the treatment of mucinous tumours. Am J Cancer Res. 2023;13(4):1522–32
Fisher OM, Leverett M, Wullschleger ME, et al. The mucolytic agent bromelain and N-acetylcysteine in a murine model of appendiceal pseudomyxoma peritonei. Am J Cancer Res. 2021;11(6):3046–60
Ke K, Pillai K, Mekkawy AH, et al. The effect of intraperitoneal administration of BromAc on blood parameters: phase 1 study. Discov Onc. 2021;12:25. doi:10.1007/s12672-021-00418-5
Valle SJ, Akhter J, Mekkawy AH, et al. A novel treatment of bromelain and acetylcysteine (BromAc) in patients with peritoneal mucinous tumours: a phase I first in man study. Eur J Surg Oncol. 2021;47(1):115–22. doi:10.1016/j.ejso.2019.10.033
Yang J, Glenn D, Lodh S, Valle S, Morris DL. Long-Term Treatment of Unresectable Pseudomyxoma Peritonei with Multiple Treatments of Intratumoural Bromelain and Acetylcysteine (BromAc®): A Case Report. Case Rep Oncol. 2023 Dec 8;16(1):1551-1556. doi: 10.1159/000534202.
Rodríguez-Ortiz L, Vázquez-Borrego MC, Bura FI, et al. Intra-tumoural bromelain and N-acetylcysteine for recurrent and unresectable pseudomyxoma peritonei: phase I/II trial. Br J Surg. 2024;111(3):znae045. doi:10.1093/bjs/znae045
Raghav KP, Shetty AV, Kazmi SM, et al. Impact of molecular alterations and targeted therapy in appendiceal adenocarcinomas. Oncologist. 2013;18(12):1270–7. doi:10.1634/theoncologist.2013-0186
Bevan KE, Mohamed F, Moran BJ. Pseudomyxoma peritonei. World J Gastrointest Oncol. 2016;8(6):494–500
Valasek MA, Pai RK. The molecular and genetic basis of appendiceal mucinous neoplasms. Pathology. 2018;50(2):149–55
Flatmark K, Torgunrud A, Fleten KG, et al. Peptide vaccine targeting mutated GNAS: a potential novel treatment for pseudomyxoma peritonei. J Immunother Cancer. 2021;9(10):e003109. doi:10.1136/jitc-2021-003109
